← Back to Screener
Jaguar Health, Inc. (JAGX)
Price$0.41
Favorite Metrics
Price vs S&P 500 (26W)-87.65%
Price vs S&P 500 (4W)-5.48%
Market Capitalization$5.34M
All Metrics
Book Value / Share (Quarterly)$1.53
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-1.26%
Cash Flow / Share (Quarterly)$-3.40
Price vs S&P 500 (YTD)-59.92%
Gross Margin (TTM)67.21%
Net Profit Margin (TTM)-464.20%
EPS (TTM)$-37.59
10-Day Avg Trading Volume0.73M
EPS Excl Extra (TTM)$-37.59
Revenue Growth (5Y)4.17%
EPS (Annual)$-22.91
ROI (Annual)-84.95%
Gross Margin (Annual)67.21%
Net Profit Margin (5Y Avg)-565.36%
Cash / Share (Quarterly)$0.14
Revenue Growth QoQ (YoY)-7.81%
ROA (Last FY)-139.43%
Revenue Growth TTM (YoY)-1.52%
EBITD / Share (TTM)$-21.65
ROE (5Y Avg)-412.67%
Operating Margin (TTM)-414.45%
Cash Flow / Share (Annual)$-3.40
P/B Ratio0.95x
P/B Ratio (Quarterly)1.46x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)4.07x
Net Interest Coverage (TTM)-7.53x
ROA (TTM)-113.98%
EPS Incl Extra (Annual)$-22.91
Current Ratio (Annual)0.50x
Quick Ratio (Quarterly)0.23x
3-Month Avg Trading Volume2.76M
52-Week Price Return-92.56%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.89
P/S Ratio (Annual)0.46x
Asset Turnover (Annual)0.30x
52-Week High$15.48
Operating Margin (5Y Avg)-448.71%
EPS Excl Extra (Annual)$-22.91
CapEx CAGR (5Y)42.41%
26-Week Price Return-80.76%
Quick Ratio (Annual)0.23x
13-Week Price Return-46.40%
Total Debt / Equity (Annual)3.64x
Current Ratio (Quarterly)0.50x
Enterprise Value$46.89
Revenue / Share Growth (5Y)-72.48%
Asset Turnover (TTM)0.25x
Book Value / Share Growth (5Y)319.19%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.40x
Pretax Margin (Annual)-469.09%
Cash / Share (Annual)$0.14
3-Month Return Std Dev223.78%
Gross Margin (5Y Avg)71.78%
Net Income / Employee (TTM)$-1
ROE (Last FY)-393.98%
Net Interest Coverage (Annual)-7.53x
EPS Basic Excl Extra (Annual)$-22.91
Receivables Turnover (TTM)7.55x
Total Debt / Equity (Quarterly)5.47x
EPS Incl Extra (TTM)$-37.59
Receivables Turnover (Annual)7.55x
ROI (TTM)-100.53%
P/S Ratio (TTM)0.46x
Pretax Margin (5Y Avg)-570.46%
Revenue / Share (Annual)$4.94
Tangible BV / Share (Annual)$-5.37
Price vs S&P 500 (52W)-127.20%
Year-to-Date Return-55.99%
5-Day Price Return0.94%
EPS Normalized (Annual)$-22.91
ROA (5Y Avg)-98.32%
Net Profit Margin (Annual)-464.20%
Month-to-Date Return10.61%
Cash Flow / Share (TTM)$-3.41
EBITD / Share (Annual)$-19.62
Operating Margin (Annual)-414.45%
LT Debt / Equity (Annual)2.41x
ROI (5Y Avg)-111.61%
LT Debt / Equity (Quarterly)1.36x
EPS Basic Excl Extra (TTM)$-37.59
P/TBV (Quarterly)26.17x
P/B Ratio (Annual)1.22x
Inventory Turnover (TTM)0.40x
Pretax Margin (TTM)-469.09%
Book Value / Share (Annual)$461.94
Price vs S&P 500 (13W)-48.78%
Beta0.45x
Revenue / Share (TTM)$2.17
ROE (TTM)-582.86%
52-Week Low$0.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
JAGXJaguar Health, Inc. | 0.46x | -1.52% | 67.21% | — | $0.41 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Jaguar Health is a commercial-stage biopharmaceutical company developing plant-based, non-opioid prescription medicines for gastrointestinal disorders, primarily chronic diarrhea. Its lead product, Mytesi, is a first-in-class anti-secretory agent with potential applications across multiple GI indications in both human and animal health markets. The company generates revenue primarily from its human health segment.